Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Front Immunol ; 14: 1155182, 2023.
Article in English | MEDLINE | ID: mdl-37275857

ABSTRACT

Background: Solute carrier family 35 member A2 (SLC35A2), which belongs to the SLC35 solute carrier family of human nucleoside sugar transporters, has shown regulatory roles in various tumors and neoplasms. However, the function of SLC35A2 across human cancers remains to be systematically assessed. Insights into the prediction ability of SLC35A2 in clinical practice and immunotherapy response remains limited. Materials and methods: We obtained the gene expression and protein levels of SLC35A2 in a variety of tumors from Molecular Taxonomy of Breast Cancer International Consortium, The Cancer Genome Atlas, Gene Expression Omnibus, Chinese Glioma Genome Atlas, and Human Protein Atlas databases. The SLC35A2 level was validated by immunohistochemistry. The predictive value for prognosis was evaluated by Kaplan-Meier survival and Cox regression analyses. Correlations between SLC35A2 expression and DNA methylation, genetic alterations, tumor mutation burden (TMB), microsatellite instability (MSI), and tumor microenvironment were performed using Spearman's correlation analysis. The possible downstream pathways of SLC35A2 in different human cancers were explored using gene set variation analysis. The potential role of SLC35A2 in the tumor immune microenvironment was evaluated via EPIC, CIBERSORT, MCP-counter, CIBERSORT-ABS, quanTIseq, TIMER, and xCell algorithms. The difference in the immunotherapeutic response of SLC35A2 under different expression conditions was evaluated by the tumor immune dysfunction and exclusion (TIDE) score as well as four independent immunotherapy cohorts, which includes patients with bladder urothelial carcinoma (BLCA, N = 299), non-small cell lung cancer (NSCLC, N = 72 and N = 36) and skin cutaneous melanoma (SKCM, N = 25). Potential drugs were identified using the CellMiner database and molecular docking. Results: SLC35A2 exhibited abnormally high or low expression in 23 cancers and was significantly associated with the prognosis. In various cancers, SLC35A2 expression and mammalian target of rapamycin complex 1 signaling were positively correlated. Multiple algorithmic immune infiltration analyses suggested an inverse relation between SLC35A2 expression and infiltrating immune cells, which includes CD4+T cells, CD8+T cells, B cells, and natural killer cells (NK) in various tumors. Furthermore, SLC35A2 expression was significantly correlated with pan-cancer immune checkpoints, TMB, MSI, and TIDE genes. SLC35A2 showed significant predictive value for the immunotherapy response of patients with diverse cancers. Two drugs, vismodegib and abiraterone, were identified, and the free binding energy of cytochrome P17 with abiraterone was higher than that of SLC35A2 with abiraterone. Conclusion: Our study revealed that SLC35A2 is upregulated in 20 types of cancer, including lung adenocarcinoma (LUAD), breast invasive carcinoma (BRCA), colon adenocarcinoma (COAD), and lung squamous cell carcinoma (LUSC). The upregulated SLC35A2 in five cancer types indicates a poor prognosis. Furthermore, there was a positive correlation between the overexpression of SLC35A2 and reduced lymphocyte infiltration in 13 cancer types, including BRCA and COAD. Based on data from several clinical trials, patients with LUAD, LUSC, SKCM, and BLCA who exhibited high SLC35A2 expression may experience improved immunotherapy response. Therefore, SLC35A2 could be considered a potential predictive biomarker for the prognosis and immunotherapy efficacy of various tumors. Our study provides a theoretical basis for further investigating its prognostic and therapeutic potentials.


Subject(s)
Biomarkers, Tumor , Monosaccharide Transport Proteins , Neoplasms , Humans , Gene Expression , Immunotherapy , Monosaccharide Transport Proteins/genetics , Mutation , Neoplasms/genetics , Neoplasms/immunology , Neoplasms/therapy , Prognosis , T-Lymphocytes/immunology , Treatment Outcome , Tumor Microenvironment , Up-Regulation , Biomarkers, Tumor/genetics
2.
Urology ; 166: 126-132, 2022 08.
Article in English | MEDLINE | ID: mdl-35490902

ABSTRACT

OBJECTIVE: To investigate the efficacy of muscle-derived stem cells (MDSCs) combined with nerve growth factor (NGF) in the treatment of stress urinary incontinence (SUI) METHODS: MDSCs were isolated and extracted from 90 SD rats, and the stem cell characteristics of the cells were identified using flow cytometry. NGF overexpression (oe-NGF) plasmid was coated with adenovirus and qRT-PCR was applied to verify adenovirus transfection efficiency. The rat models of SUI were constructed and randomly divided into 5 groups: control group, phosphate buffer (PBS) group, MDSCs + oe-NGF group, MDSCs + vector group, and MDSCs group. After 8 weeks of feeding, the leakage point pressure (LPP) rats, and Masson staining of rat urethral sections were detected. The expression of NGF and vascular endothelial growth factor (VEGF) was detected by western blot and IHC staining. RESULTS: Compared with the control group, the LPP and the ratio of muscle fibers/collagen fibers were significantly increased in the MDSCs treated groups, with the highest increase in the MDSCs + oe-NGF group. Western blot and IHC results showed that the expression of NGF and VEGF in the urethral tissues in the MDSCs treated groups were significantly up-regulated comparing with the control group, with the highest increase in the MDSCs + oe-NGF group. CONCLUSION: MDSCs alone can relieve SUI, while MDSCs combined with NGF is more effective, which may be related to the up-regulating of VEGF.


Subject(s)
Urinary Incontinence, Stress , Animals , Muscles/metabolism , Nerve Growth Factor , Rats , Rats, Sprague-Dawley , Stem Cell Transplantation/methods , Urinary Incontinence, Stress/surgery , Vascular Endothelial Growth Factor A/metabolism
3.
Biomed Res Int ; 2020: 4830847, 2020.
Article in English | MEDLINE | ID: mdl-32685491

ABSTRACT

Clear cell renal cell carcinoma (ccRCC) is a very common cancer in urology. Many evidences suggest that complex changed pathways take a nonnegligible part in the occurrence and development of ccRCC. Nevertheless, the underlying mechanism is not clear. In this study, the expression data between ccRCC and normal tissue samples in TCGA database were compared to distinguish differentially expressed genes (DEGs: mRNAs, miRNAs, and lncRNAs). Afterwards, we used GO enrichment and KEGG pathway enrichment analyses to explore the functions of these DEGs. We also found the correlation between three RNAs and created a competing endogenous RNA (ceRNA) network. Moreover, we used univariate Cox regression analysis to select DEGs that are connected with overall survival (OS) of ccRCC patients. We found 1652 mRNAs, 1534 lncRNAs, and 173 miRNAs that were distinguished in ccRCC compared with normal tissues. According to GO analysis, the maladjusted mRNAs are mainly concentrated in immune cell activation and kidney development, while according to KEGG, they are mainly concentrated in pathways related to cancer. A total of 5 mRNAs, 1 miRNA, and 4 lncRNAs were connected with patients' OS. In this article, a network of lncRNA-miRNA-mRNA was established; it is expected to be able to indicate possible molecular mechanisms for initial of ccRCC and provide a new viewpoint for diagnosis of ccRCC.


Subject(s)
Carcinoma, Renal Cell , Databases, Nucleic Acid , Gene Expression Regulation, Neoplastic , Kidney Neoplasms , RNA, Viral , Carcinoma, Renal Cell/genetics , Carcinoma, Renal Cell/metabolism , Carcinoma, Renal Cell/mortality , Disease-Free Survival , Female , Humans , Kidney Neoplasms/genetics , Kidney Neoplasms/metabolism , Kidney Neoplasms/mortality , Male , Predictive Value of Tests , RNA, Viral/biosynthesis , RNA, Viral/genetics , Survival Rate
4.
Opt Express ; 27(8): 11503-11509, 2019 Apr 15.
Article in English | MEDLINE | ID: mdl-31052993

ABSTRACT

Diffraction beams generated by an acousto-optic modulator (AOM) are widely used in various optical experiments, some of which require high angular stability with the temporal modulation of optical power. Usually, it is difficult to realize both angular stability and high-power modulation in a passive setup without a servo system of radio-frequency compensation. Here, we present a method to suppress the angular drift and pointing noise only with the thermal management of the AOM crystal. We analyze the dependence of the angular drift on the refractive index variation and find that the angular drift is very sensitive to the temperature gradient, which could induce the refractive index gradient inside the AOM crystal. It reminds us that such angular drift could be significantly suppressed by carefully overlapping the zero temperature gradient area with the position of the acousto-optic interaction zone. We implement a water-cooling setup and find that the angular drift of an AOM is reduced over 100 times during the thermal transient and the angular noise is also suppressed to one-third of the non-cooled case. It should be emphasized that this thermal control method generally used to suppress the beam drift in both the diffraction and the perpendicular-to-diffraction directions. The refractive index thermal coefficient of tellurium dioxide crystal at 1064 nm determined by this angular drift-temperature model is 16×10 -6 K -1, consistent with previous studies. This thermal control technique provides potential applications for optical trapping and remote sensoring that demand for intensity ramps.

SELECTION OF CITATIONS
SEARCH DETAIL
...